Top Markets
Coin of the day
Enimmune corporation Enimmune corporation

Enimmune corporation

6564
Rangering i aksjer #26781
Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused... Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused on the research, development, and commercialization of pharmaceutical products. Among its key offerings is Tuberculin PPD RT23 SSI, an approved diagnostic agent utilized in tuberculin tests to ascertain the presence of tuberculosis infection in patients. Beyond its existing products, Enimmune is heavily invested in developing vaccines aimed at combating a diverse array of infectious diseases. These include, but are not limited to, vaccines for enterovirus, pneumonia, norovirus, dengue fever, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Established in 2014, the company maintains its headquarters in Taichung City, Taiwan.
Aksjekurs
$0.52468396
Markedsverdi
$37.85M
Endring (1 dag)
1.23%
Endring (1 år)
-4.53%
Land
TW
Handel Enimmune corporation (6564)

Kategori

P/S-forhold for Enimmune corporation (6564)
P/S-forhold per 2026 TTM: 0
Ifølge Enimmune corporation sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Enimmune corporation fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH